LB Pharmaceuticals Inc (LBRX:NASDAQ) closed at $38.73 on October 23, 2026, down 1.75% on the day. The stock trades 22.8% below its 52-week high of $50.16 and 170.5% above its 52-week low of $14.32. Over the past year, it gained 142.5%. LB Pharmaceuticals Inc is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, LBRX closed higher on 125 days (50%). Its best day was December 8, 2025 (+15.38%) and its worst was January 12, 2026 (-8.20%). The stock moved 10% or more in a single session 6 times.
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Find more stocks like LBRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.